Obseva SA (NASDAQ:OBSV) Sees Large Increase in Short Interest

Obseva SA (NASDAQ:OBSV) saw a large growth in short interest during the month of November. As of November 29th, there was short interest totalling 464,600 shares, a growth of 9.5% from the November 14th total of 424,300 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily volume of 462,300 shares, the short-interest ratio is currently 1.0 days.

NASDAQ OBSV opened at $3.35 on Friday. Obseva has a one year low of $2.37 and a one year high of $15.66. The company has a 50-day simple moving average of $4.67 and a 200-day simple moving average of $8.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.65 and a current ratio of 3.65. The firm has a market capitalization of $154.62 million, a PE ratio of -1.75 and a beta of 0.57.

Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.19. Equities analysts forecast that Obseva will post -2.6 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wedbush Securities Inc. boosted its stake in Obseva by 54.2% during the 3rd quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock valued at $334,000 after purchasing an additional 14,100 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Obseva by 263.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock valued at $37,000 after purchasing an additional 2,372 shares during the period. Morgan Stanley boosted its stake in Obseva by 358.6% during the 2nd quarter. Morgan Stanley now owns 3,100 shares of the company’s stock valued at $35,000 after purchasing an additional 2,424 shares during the period. AXA boosted its stake in Obseva by 7.8% during the 2nd quarter. AXA now owns 500,313 shares of the company’s stock valued at $5,659,000 after purchasing an additional 36,356 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Obseva by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock valued at $900,000 after purchasing an additional 5,600 shares during the period. 63.53% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently commented on OBSV. Zacks Investment Research raised shares of Obseva from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Credit Suisse Group lowered shares of Obseva from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $16.00 to $4.00 in a report on Friday, November 8th. Wedbush reaffirmed a “buy” rating and issued a $38.00 price target on shares of Obseva in a report on Thursday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target (down from $44.00) on shares of Obseva in a report on Monday, December 2nd. Finally, BidaskClub raised shares of Obseva from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $22.00.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Read More: Why Invest in High-Yield Dividend Stocks?

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.